Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC

But Competition Intensifying

23 Apr 2020

Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.

New top-line Phase III results show that a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) had a significant benefit in progression-free survival (PFS) compared with monotherapy Sutent (sunitinib) in the first-line treatment of renal cell carcinoma (RCC), positioning the dual therapy as a contender in an increasingly competitive field.

The benefits for Ono Pharmaceutical Co. Ltd./Bristol-Myers Squibb Co.’s Opdivo in the indication may be particularly significant, given the potential for improved toxicity versus the anti-PD-1 antibody’s currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

31 May 2025

• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.